Griffin: Accessing functional antibodies from serum without B cells
Griffin is a platform for sequencing polyclonal antibodies using mass spectrometry. Since 2009, Abterra Biosciences founders and employees have been developing novel methods for sequencing antibody proteins directly. Our monoclonal antibody sequencing service, Valens, has been used to successfully sequence hundreds of antibodies without the need for B cells. Now, with Griffin, we can sequencing complex mixes of antibodies directly from patient serum, or from immunized animals.
Watch our CEO, Dr. Natalie Castellana’s presentation on Unlocking the Serum Antibody Repertoire: Accessing Functional Antibodies without B Cells to learn how Griffin works.
Click below to watch the presentation.
Related Posts
We are a CONNECT Cool Company 2021!
We’re excited to announce that Abterra Biosciences has been selected as "A Cool Company" for the second year in a row by CONNECT. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences...
Problem Solvers by Nature
"When @necastellana began applying algorithms for protein analysis, she realized that most methods did not utilize the power of the human body’s adaptive immune system." Read about how to unlock the power of the human immune system using bioinformatics. Get In...
Alicanto Antibody Discovery – Diversity
Alicanto® is Abterra Biosciences' proprietary antibody discovery platform that mines the entire immune response to identify diverse, functional antibodies. For an overview of the proteogenomic process, read more about Alicanto®. Alicanto benefits include: Full...
Get In Touch